BS_D7XRFE0R
Diffuse intrinsic pontine glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Diffuse intrinsic pontine glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Diffuse intrinsic pontine glioma
- overall_survival_months
- 16.918528252299605
- age_years
- 10.016
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.619
- G2M_CHECKPOINT+0.536
- E2F_TARGETS+0.519
- INTERFERON_GAMMA_RESPONSE+0.482
- MYC_TARGETS_V2+0.443
- MITOTIC_SPINDLE+0.421
- PROTEIN_SECRETION+0.414
- MYC_TARGETS_V1+0.362
- PI3K_AKT_MTOR_SIGNALING+0.318
- UNFOLDED_PROTEIN_RESPONSE+0.288
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.352
- MYOGENESIS-0.293
- APICAL_SURFACE-0.260
- KRAS_SIGNALING_DN-0.243
- ANGIOGENESIS-0.226
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.220
- UV_RESPONSE_UP-0.204
- ESTROGEN_RESPONSE_EARLY-0.202
- ESTROGEN_RESPONSE_LATE-0.187
- APICAL_JUNCTION-0.157
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934882 | — | — | 0.895 |
| 2 | 3F932445-1D8F-4128-A8DA-F36EA9F6E745 | — | — | 0.889 |
| 3 | SRR934975 | — | — | 0.880 |
| 4 | 64F4FE1B-1B96-49CC-B4E9-454D971DB7BC | — | — | 0.878 |
| 5 | SRR934878 | — | — | 0.876 |
| 6 | sclcMAD13022_S60.txt | — | cohortMD1 | 0.875 |
| 7 | E35A6AA5-331F-489B-8CE1-9D0BC4CDE119 | — | — | 0.868 |
| 8 | 57AA1143-0FA1-4197-8CBE-517F6B885753 | — | — | 0.857 |
| 9 | SRR934865 | — | — | 0.856 |
| 10 | MDT-AP-3168 | Med | Medulloblastoma | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.619 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.536 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.519 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.482 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.443 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.421 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.414 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.362 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.318 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.288 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.263 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.246 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.232 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.205 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.172 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.166 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.164 | Idelalisib | — uncovered |
| PEROXISOME | 0.157 | Idelalisib | — uncovered |
| COMPLEMENT | 0.144 | Inavolisib | — uncovered |